Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT00002902
Phase
PHASE1
Status
Completed

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus ICI D1694 in treating patients with advanced solid tumors.

Key Dates

Start date
Apr 30, 1997
Status verified
Jul 2002

Study Design

Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
University of Pennsylvania Cancer CenterPhiladelphiaPennsylvania19104-

Find similar trials in Philadelphia, PA

By research site
University of Pennsylvania Cancer Center· Philadelphia, PA

Related Studies